{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:10:00Z","timestamp":1791727800258,"version":"4.3.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10067-026-08101-2","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T09:20:43Z","timestamp":1775640043000},"page":"3865-3879","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chimeric antigen receptor macrophage (CAR-M) immunotherapy in autoimmune inflammatory rheumatic diseases"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8602-0958","authenticated-orcid":false,"given":"Ian C.","family":"Chikanza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7670-3314","authenticated-orcid":false,"given":"Lazaros I.","family":"Sakkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"issue":"3","key":"8101_CR1","first-page":"147","volume":"18","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M, Brentjens RJ (2018) Chimeric antigen receptor therapy. Nat Rev Immunol 18(3):147\u2013159","journal-title":"Nat Rev Immunol"},{"issue":"591","key":"8101_CR2","volume":"13","author":"MA Morrissey","year":"2021","unstructured":"Morrissey MA, Williamson JC (2021) Engineering macrophages with chimeric antigen receptors. Sci Transl Med 13(591):eabb8216","journal-title":"Sci Transl Med"},{"key":"8101_CR3","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky M, Ruella M, Shestova O et al (2020) Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol 38:947\u201353","journal-title":"Nat Biotechnol"},{"issue":"5","key":"8101_CR4","volume":"132","author":"L Zhang","year":"2022","unstructured":"Zhang L, Hong H, Song X (2022) Development of CAR-M cells: methods and applications. J Clin Invest 132(5):e153110","journal-title":"J Clin Invest"},{"issue":"12","key":"8101_CR5","first-page":"1832","volume":"7","author":"Y Liu","year":"2019","unstructured":"Liu Y, Fang X, Wang L (2019) CAR-M cells in tumor immunotherapy. Cancer Immunol Res 7(12):1832\u20131842","journal-title":"Cancer Immunol Res"},{"key":"8101_CR6","volume":"11","author":"X Wang","year":"2020","unstructured":"Wang X, Zhao Z, Li H (2020) Signaling domains for CAR-M cells. Front Immunol 11:577547","journal-title":"Front Immunol"},{"issue":"14","key":"8101_CR7","first-page":"3996","volume":"27","author":"NR Anderson","year":"2021","unstructured":"Anderson NR, Minutolo NG, Gill S (2021) Preclinical models of CAR-M therapy for solid tumors. Clin Cancer Res 27(14):3996\u20134008","journal-title":"Clin Cancer Res"},{"issue":"3","key":"8101_CR8","first-page":"673","volume":"184","author":"IL Weissman","year":"2021","unstructured":"Weissman IL, Matsushita M, Anderson K (2021) Targeting glioblastoma with CAR-M cells. Cell 184(3):673\u2013681","journal-title":"Cell"},{"issue":"13","key":"8101_CR9","first-page":"3013","volume":"4","author":"M Sadelain","year":"2020","unstructured":"Sadelain M, Brentjens RJ, Rivi\u00e8re I (2020) CAR-M potential in hematological malignancies. Blood Adv 4(13):3013\u20133021","journal-title":"Blood Adv"},{"issue":"1","key":"8101_CR10","volume":"13","author":"SU Seo","year":"2022","unstructured":"Seo SU, Kweon MN, Kim YJ (2022) Exploring CAR-M technology in infectious diseases. Nat Commun 13(1):1302","journal-title":"Nat Commun"},{"issue":"1","key":"8101_CR11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.it.2020.10.013","volume":"42","author":"MP Colombo","year":"2021","unstructured":"Colombo MP, Piconese S, Belkaid Y (2021) Immunomodulatory roles of CAR-M cells in autoimmune diseases. Trends Immunol 42(1):76\u201388","journal-title":"Trends Immunol"},{"issue":"6","key":"8101_CR12","doi-asserted-by":"crossref","DOI":"10.1084\/jem.169.6.2191","volume":"219","author":"T Saito","year":"2022","unstructured":"Saito T, Nakagawa R, Yoshida M (2022) CAR-M cells for solid tumor immunotherapy. J Exp Med 219(6):e20212460","journal-title":"J Exp Med"},{"issue":"12","key":"8101_CR13","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.ccell.2021.11.008","volume":"39","author":"M Feng","year":"2021","unstructured":"Feng M, Meng Y, Cheng X (2021) Tumor microenvironment modulation by CAR-M cells. Cancer Cell 39(12):1560\u20131572","journal-title":"Cancer Cell"},{"issue":"4","key":"8101_CR14","first-page":"597","volume":"52","author":"M Dougan","year":"2020","unstructured":"Dougan M, Dranoff G, Rudra D (2020) Enhanced antigen presentation with CAR-M technology. Immunity 52(4):597\u2013613","journal-title":"Immunity"},{"issue":"5","key":"8101_CR15","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.ymthe.2022.03.016","volume":"30","author":"Y Wang","year":"2022","unstructured":"Wang Y, Li X, Chen G (2022) Manufacturing challenges of CAR-M cells. Mol Ther 30(5):1911\u20131922","journal-title":"Mol Ther"},{"issue":"8","key":"8101_CR16","first-page":"471","volume":"17","author":"MV Maus","year":"2020","unstructured":"Maus MV, Fraietta JA (2020) Safety concerns of CAR-M therapy. Nat Rev Clin Oncol 17(8):471\u2013485","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"8101_CR17","first-page":"e70","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Bishop MR, Tam CS (2021) Clinical data on CAR-M cells. Lancet Oncol 22(2):e70-81","journal-title":"Lancet Oncol"},{"issue":"7","key":"8101_CR18","volume":"20","author":"H Lee","year":"2021","unstructured":"Lee H, Kim J (2021) CAR-M cells in inflammatory diseases. Autoimmun Rev 20(7):102877","journal-title":"Autoimmun Rev"},{"issue":"1","key":"8101_CR19","first-page":"22","volume":"83","author":"E Brown","year":"2024","unstructured":"Brown E, White T, Green M (2024) Clinical trials of CAR-M cells in autoimmune diseases. Ann Rheum Dis 83(1):22\u201330","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"8101_CR20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10067-022-06377-8","volume":"42","author":"RA Green","year":"2023","unstructured":"Green RA, Thompson LM, Patel S (2023) Novel approaches to treating rheumatoid arthritis with CAR-M therapy. Clin Rheumatol 42(1):15\u201326","journal-title":"Clin Rheumatol"},{"issue":"2","key":"8101_CR21","volume":"9","author":"S Patel","year":"2022","unstructured":"Patel S, Kumar N, Mehta V (2022) Harnessing macrophages for therapeutic interventions in SLE. Lupus Sci Med 9(2):e000548","journal-title":"Lupus Sci Med"},{"issue":"3","key":"8101_CR22","first-page":"432","volume":"75","author":"AL Smith","year":"2023","unstructured":"Smith AL, Brown CJ, Wang X (2023) Targeting fibroblast activation protein with CAR-M cells in rheumatoid arthritis. Arthritis Rheumatol 75(3):432\u2013441","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"8101_CR23","first-page":"1234","volume":"198","author":"M Johnson","year":"2022","unstructured":"Johnson M, Smith RL, Davis KP (2022) Macrophage-based therapies in autoimmunity. J Immunol 198(4):1234\u20131245","journal-title":"J Immunol"},{"issue":"4","key":"8101_CR24","volume":"3","author":"D Thompson","year":"2021","unstructured":"Thompson D, Roberts EJ, Li Z (2021) Challenges in CAR-M cell development. Immunother Adv 3(4):ltab012","journal-title":"Immunother Adv"},{"key":"8101_CR25","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1002\/art.1780351107","volume":"35","author":"IC Chikanza","year":"1992","unstructured":"Chikanza IC, Petrou P, Kingsley G, Chrousos G, Panayi GS (1992) Defective hypothalamic responses to immune and inflammatory stimuli in patients with rheumatoid arthritis. Arthritis Rheum 35:1281\u20131288","journal-title":"Arthritis Rheum"},{"key":"8101_CR26","doi-asserted-by":"crossref","unstructured":"Chikanza IC, Sakka LI (2026) Cell immunotherapy in autoimmune rheumatic diseases: a paradigm shift in the therapy of autoimmune inflammatory rheumatic diseases. Clin Rheumatol. (In press)","DOI":"10.1007\/s10067-026-08103-0"},{"key":"8101_CR27","doi-asserted-by":"crossref","unstructured":"Chikanza IC (1996) The neuroendocrine immunology of rheumatoid arthritis. In: Chikanza IC (ed). Balliere\u2019s Clinical Rheumatology: The Neuroendocrine Immune Basis of Rheumatic Diseases. vol 10(2), London: Bailli\u00e8re Tindall, pp 273\u201394","DOI":"10.1016\/S0950-3579(96)80018-5"},{"issue":"23","key":"8101_CR28","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB McInnes","year":"2011","unstructured":"McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365(23):2205\u20132219","journal-title":"N Engl J Med"},{"key":"8101_CR29","doi-asserted-by":"publisher","unstructured":"Chikanza IC, Trollip S, Sakkas LI (2024) Regulatory T cells and autoimmunity. In: Dwivedi MK, Fairweather D (eds) Regulatory T Cells and Autoimmune Diseases. Academic Press, pp 41\u201356. https:\/\/doi.org\/10.1016\/B978-0-443-13947-5.00007-5.","DOI":"10.1016\/B978-0-443-13947-5.00007-5"},{"key":"8101_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102397","volume":"18","author":"S Tardito","year":"2019","unstructured":"Tardito S, Martinelli G, Soldano S et al (2019) Macrophage M1\/M2 polarization and rheumatoid arthritis: a systematic review. Autoimmun Rev 18:102397","journal-title":"Autoimmun Rev"},{"key":"8101_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adj1252","volume":"10","author":"MM Hanlon","year":"2024","unstructured":"Hanlon MM, Smith CM, Canavan M et al (2024) Loss of synovial tissue macrophage homeostasis precedes rheumatoid arthritis clinical onset. Sci Adv 10:eadj1252","journal-title":"Sci Adv"},{"key":"8101_CR32","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s10067-015-2902-5","volume":"34","author":"L Sakkas","year":"2015","unstructured":"Sakkas L, Simipoulou T, Bogdanos D, Chikanza IC (2015) Early systemic sclerosis: opportunities for treatment. Clin Rheumatol 34:1327\u20131331","journal-title":"Clin Rheumatol"},{"issue":"2","key":"8101_CR33","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/rheumatology\/keac410","volume":"62","author":"Y Al-Adwi","year":"2023","unstructured":"Al-Adwi Y, Westra J, van Goor H et al (2023) Macrophages as determinants and regulators of fibrosis in systemic sclerosis. Rheumatology (Oxford) 62(2):535\u2013545","journal-title":"Rheumatology (Oxford)"},{"key":"8101_CR34","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s12016-021-08889-8","volume":"64","author":"ME Truchetet","year":"2023","unstructured":"Truchetet ME, Brembilla NC, Chizzolini C (2023) Current concepts on the pathogenesis of systemic sclerosis. Clin Rev Allergy Immunol 64:262\u2013283","journal-title":"Clin Rev Allergy Immunol"},{"issue":"8","key":"8101_CR35","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1136\/ard-2022-223741","volume":"82","author":"MK Crow","year":"2023","unstructured":"Crow MK (2023) Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets. Ann Rheum Dis 82(8):999\u20131010","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"8101_CR36","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3899\/jrheum.2023-0833","volume":"51","author":"AS Yennemadi","year":"2024","unstructured":"Yennemadi AS, Jordan N, Diong S, Keane J, Leisching G (2024) Dysregulated immunometabolism and vascular damage in SLE. J Rheumatol 51(3):234\u2013241","journal-title":"J Rheumatol"},{"key":"8101_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-025-09025-6","volume":"68","author":"C Wang","year":"2025","unstructured":"Wang C, Chen B, Yu X, Guan X (2025) Macrophages unmasked: their pivotal role in driving atherosclerosis in systemic lupus erythematosus. Clin Rev Allergy Immunol 68:10","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"8101_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24031846","volume":"24","author":"S La Bella","year":"2023","unstructured":"La Bella S, Rinaldi M, Di Ludovico A et al (2023) Genetic background and molecular mechanisms of juvenile idiopathic arthritis. Int J Mol Sci 24(3):1846","journal-title":"Int J Mol Sci"},{"issue":"1","key":"8101_CR39","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4049\/jimmunol.1900721","volume":"204","author":"S Mahajan","year":"2020","unstructured":"Mahajan S, Mellins ED, Faccio R (2020) Diacylglycerol kinase \u03b6 regulates macrophage responses in juvenile arthritis and cytokine storm syndrome mouse models. J Immunol 204(1):137\u2013146","journal-title":"J Immunol"},{"key":"8101_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-023-03032-8","volume":"25","author":"N Inoue","year":"2023","unstructured":"Inoue N, Schulert GS (2023) Mouse models of systemic juvenile idiopathic arthritis and macrophage activation syndrome. Arthritis Res Ther 25:48","journal-title":"Arthritis Res Ther"},{"key":"8101_CR41","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/gene.2012.3","volume":"13","author":"A Ravelli","year":"2012","unstructured":"Ravelli A, Grom AA, Behrens EM, Cron RQ (2012) Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis. Genes Immun 13:289\u2013298","journal-title":"Genes Immun"},{"issue":"10136","key":"8101_CR42","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","volume":"391","author":"DJ Veale","year":"2018","unstructured":"Veale DJ, Fearon U (2018) The pathogenesis of psoriatic arthritis. Lancet 391(10136):2273\u20132284","journal-title":"Lancet"},{"issue":"14","key":"8101_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411662","volume":"24","author":"BW Lee","year":"2023","unstructured":"Lee BW, Moon SJ (2023) Inflammatory cytokines in psoriatic arthritis. Int J Mol Sci 24(14):11662","journal-title":"Int J Mol Sci"},{"key":"8101_CR44","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1007\/s10787-025-01865-0","volume":"33","author":"S Sahu","year":"2025","unstructured":"Sahu S, Jain P, Deshmukh R et al (2025) Psoriatic arthritis in transition: cytokine signaling, immune dysregulation, and therapeutic innovation. Inflammopharmacology 33:4275\u201390","journal-title":"Inflammopharmacology"},{"key":"8101_CR45","unstructured":"Mandal H (2025) IL-23\/IL-17 axis in psoriatic disease: from pathogenesis to personalized treatment. Psoriasis Hub"},{"issue":"1","key":"8101_CR46","doi-asserted-by":"publisher","first-page":"144","DOI":"10.46497\/ArchRheumatol.2025.10934","volume":"40","author":"G Dilek","year":"2025","unstructured":"Dilek G, Kalcik Unan M, Nas K (2025) Immune response and cytokine pathways in psoriatic arthritis: a systematic review. Arch Rheumatol 40(1):144\u2013156","journal-title":"Arch Rheumatol"},{"issue":"Suppl 3","key":"8101_CR47","doi-asserted-by":"publisher","first-page":"iii37","DOI":"10.1136\/ard.60.90003.iii37","volume":"60","author":"PJ Mease","year":"2001","unstructured":"Mease PJ (2001) Cytokine blockers in psoriatic arthritis. Ann Rheum Dis 60(Suppl 3):iii37-40","journal-title":"Ann Rheum Dis"},{"key":"8101_CR48","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s11926-024-01136-x","volume":"26","author":"A Srinath","year":"2024","unstructured":"Srinath A, Nakamura A, Haroon N (2024) Sequence of events in the pathogenesis of axial spondyloarthritis: 2023 SPARTAN meeting proceedings. Curr Rheumatol Rep 26:133\u2013143","journal-title":"Curr Rheumatol Rep"},{"key":"8101_CR49","doi-asserted-by":"publisher","unstructured":"Siebert S, Sengupta R, Tsoukas A (2016) The pathophysiology and immunology of axial spondyloarthritis. Oxford Rheumatology Library, pp 27\u201336. https:\/\/doi.org\/10.1093\/med\/9780198755296.003.0005","DOI":"10.1093\/med\/9780198755296.003.0005"},{"issue":"2","key":"8101_CR50","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.rdc.2020.01.016","volume":"46","author":"J Ermann","year":"2020","unstructured":"Ermann J (2020) Pathogenesis of axial spondyloarthritis. Rheum Dis Clin North Am 46(2):193\u2013206","journal-title":"Rheum Dis Clin North Am"},{"key":"8101_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.623874","volume":"11","author":"D Baeten","year":"2020","unstructured":"Baeten D, Adamopoulos IE (2020) IL-23 inhibition in ankylosing spondylitis. Front Immunol 11:623874","journal-title":"Front Immunol"},{"key":"8101_CR52","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/cei.12670","volume":"183","author":"H Jethwa","year":"2016","unstructured":"Jethwa H, Bowness P (2016) The IL-23\/IL-17 axis in ankylosing spondylitis. Clin Exp Immunol 183:30\u201336","journal-title":"Clin Exp Immunol"},{"key":"8101_CR53","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0140-6736(24)02263-3","volume":"405","author":"V Navarro-Comp\u00e1n","year":"2025","unstructured":"Navarro-Comp\u00e1n V, Sepriano A, Capelusnik D, Baraliakos X (2025) Axial spondyloarthritis. Lancet 405:159\u2013172","journal-title":"Lancet"},{"issue":"5","key":"8101_CR54","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1001\/jama.2024.20917","volume":"333","author":"M Bittar","year":"2025","unstructured":"Bittar M, Deodhar A (2025) Axial spondyloarthritis: a review. JAMA 333(5):408\u2013420","journal-title":"JAMA"},{"key":"8101_CR55","unstructured":"NICE Clinical Knowledge Summaries\u00a0(2024) Disease-modifying antirheumatic drugs (DMARDs)"},{"key":"8101_CR56","doi-asserted-by":"crossref","unstructured":"Ramos S, Bredemeier M, Sol\u00f3rzano C et al (2024) The effect of combinations of conventional synthetic DMARDs on the safety and treatment retention of biologic agents or JAK inhibitors in rheumatoid arthritis: BiobadaBrasil registry. Ann Rheum Dis 83(Suppl 1):1525","DOI":"10.1136\/annrheumdis-2024-eular.1447"},{"key":"8101_CR57","unstructured":"Versus Arthritis. Disease-modifying anti-rheumatic drugs (DMARDs. Available from: https:\/\/www.arthritis-uk.org\/information-and-support\/understanding-arthritis\/arthritis-treatments\/drugs\/disease-modifying-anti-rheumatic-drugs-dmards\/. Accessed 2024"},{"issue":"4","key":"8101_CR58","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0889-857X(05)70176-9","volume":"26","author":"IC Chikanza","year":"2000","unstructured":"Chikanza IC, Weitse Kuis W, Heijnen CJ (2000) The influence of the hormonal system on pediatric rheumatic diseases. Rheum Dis Clin North Am 26(4):911\u2013925","journal-title":"Rheum Dis Clin North Am"},{"key":"8101_CR59","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1749-6632.1999.tb07624.x","volume":"876","author":"IC Chikanza","year":"1999","unstructured":"Chikanza IC (1999) Neuroendocrine immune features of paediatric inflammatory rheumatic diseases. Ann N Y Acad Sci 876:71\u201382","journal-title":"Ann N Y Acad Sci"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08101-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08101-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08101-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:02:57Z","timestamp":1783400577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08101-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["8101"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08101-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"19 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}